High frequency of hyperglycaemia observed during CAR T-cell treatment

Marieke Tienstra; Janneke W. de Boer; Jaap A. van Doesum; Tom van Meerten; Peter R. van Dijk

doi:10.1111/dme.14969

High frequency of hyperglycaemia observed during CAR T-cell treatment

Marieke Tienstra, Janneke W. de Boer, Jaap A. van Doesum, Tom van Meerten^*, Peter R. van Dijk

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Academic › peer-review

1 Citation (Scopus)

71 Downloads (Pure)

Original language	English
Number of pages	2
Journal	Diabetic Medicine
Volume	40
Issue number	2
Early online date	9-Oct-2022
DOIs	https://doi.org/10.1111/dme.14969
Publication status	Published - Feb-2023

Keywords

CAR T-cell treatment
hyperglycaemia
large B-cell lymphoma

Access to Document

10.1111/dme.14969Licence: CC BY-NC-ND

High frequency of hyperglycaemia observed during CAR T-cell treatmentFinal publisher's version, 154 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{b308d99b7f064050b8d12a45aec23721,

title = "High frequency of hyperglycaemia observed during CAR T-cell treatment",

keywords = "CAR T-cell treatment, hyperglycaemia, large B-cell lymphoma",

author = "Marieke Tienstra and {de Boer}, {Janneke W.} and {van Doesum}, {Jaap A.} and {van Meerten}, Tom and {van Dijk}, {Peter R.}",

note = "Funding Information: TvM has an advisory role by the for‐profit health care company Kite/Gilead, Janssen and has received research funding from Genentech, Celgene/BMS. The remaining authors have no relevant conflict of interest to declare.",

year = "2023",

month = feb,

doi = "10.1111/dme.14969",

language = "English",

volume = "40",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - High frequency of hyperglycaemia observed during CAR T-cell treatment

AU - Tienstra, Marieke

AU - de Boer, Janneke W.

AU - van Doesum, Jaap A.

AU - van Meerten, Tom

AU - van Dijk, Peter R.

N1 - Funding Information: TvM has an advisory role by the for‐profit health care company Kite/Gilead, Janssen and has received research funding from Genentech, Celgene/BMS. The remaining authors have no relevant conflict of interest to declare.

PY - 2023/2

Y1 - 2023/2

KW - CAR T-cell treatment

KW - hyperglycaemia

KW - large B-cell lymphoma

U2 - 10.1111/dme.14969

DO - 10.1111/dme.14969

M3 - Letter

C2 - 36209376

AN - SCOPUS:85139905857

SN - 0742-3071

VL - 40

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 2

ER -